Efforts are under way to encourage the global regulatory convergence of requirements and the use of reliance among world regulators in the area of chemistry, manufacturing and control (CMC) post-approval changes (PACs).
Key Takeaways
Heterogenous requirements together with unpredictable review, approval and implementation timelines make it very difficult for the pharmaceutical industry and regulators to put post-approval changes (PACs) in place.
Duplication of effort, a backlog of PAC requests, and the risk of product shortages are among the problems experienced by industry and regulators.
Industry wants the use of regulatory reliance and convergence procedures to be increased at global level, including maximum review periods for PACs.
The ICH Q12 guideline is intended to make the management of PACs more predictable and efficient and to reduce the regulatory burden.
The COVID-19 pandemic and the introduction of regulatory flexibilities have led to a rethink of how PACs should be managed, particularly in emergency situations and for products of early access.
Pilot programs are under way in numerous countries and at global level to test the principles of regulatory reliance and convergence.
-
The International Coalition of Medicines Regulatory Authorities is exploring the feasibility of further collaboration and convergence among regulators regarding data expectations and assessment approaches.
Efficient and harmonized PAC management by all players is key to ensuring continuous supply in the best interest of patients.
Several pilot programs are currently being conducted to test both convergence and reliance principles as way of supporting the uninterrupted...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
